New mechanistic insights into 4SC-202's epigenetic mode of action
4SC AG (4SC, FSE Prime Standard: VSC) today announced that 4SC's collaboration partner Prof. Steven A. Johnsen and his t…
4SC AG (4SC, FSE Prime Standard: VSC) today announced that 4SC's collaboration partner Prof. Steven A. Johnsen and his t…
. 4SC-202 plus checkpoint inhibition - boosting the immune system to fight cancer 4SC-202 - a potentially interesting…
RESMAIN study examines the use of resminostat as maintenance therapy in patients with advanced-stage cutaneous T-cell ly…
. - Phase II study of resminostat (RESMAIN) in cutaneous T-cell lymphoma (CTCL) on track to enrole first patient in Q4…
4SC AG (4SC, FSE Prime Standard: VSC) will host the 11th 4SC Scientific Symposium "Reprogramming cancer - overcoming dru…
Phase II trial of resminostat (RESMAIN) in cutaneous T-cell lymphoma (CTCL) on track to include first patient in Q4 2016…
4SC AG (4SC, FSE Prime Standard: VSC) today announced the formation of an international Scientific Expert Panel (iSEP).…
4SC AG (Frankfurt, Prime Standard: VSC), a biotechnology company for the research and development of targeted small mole…
The Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) today announced the…